Inside the research
GE HealthCare Technologies Inc.
GEHC Research profile · latest available data
Price overview
$66.63
▲ +0.25 (+0.4%)
| 52w hi | $88.03 |
|---|---|
| 52w lo | $59.45 |
| Vol | 4.16M |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.01
| Short | -0.20 |
|---|---|
| Medium | +0.02 |
| Long | +0.29 |
computed 2026-09-27
Key fundamentals
GE HealthCare Technologies Inc.
Healthcare · Medical Devices
| Market cap | $30.10B |
|---|---|
| Enterprise value | $38.80B |
| Trailing P/E | 15.35x |
| Forward P/E | 12.31x |
| EV / EBITDA | 10.80x |
| P / S (ttm) | 1.43x |
| Profit margin | 9.3% |
| Return on equity | 19.4% |
| Revenue growth | +5.8% |
| Earnings growth | +16.8% |
| Debt / equity | 93.97 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.30 | |
| Sector | +0.08 | |
| Technical | -0.29 | |
| Earnings | +0.00 | |
| Sentiment | +0.27 |
macro × 1.00 · 2026-09-27
Business overview
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Risk Metrics
| Beta vs SPX | 1.10 |
|---|---|
| Corr SPX | 0.51 |
| Annual vol | 34.9% |
| Annual ret | -9.0% |
| Sharpe | -0.26 |
| Max DD | -37.4% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $79.95 |
|---|---|
| High / Low | $98.00 / $65.00 |
| Median | $80.00 |
| Analysts | 19 |
| Strong Buy | 2 | |
|---|---|---|
| Buy | 10 | |
| Hold | 6 | |
| Sell | 1 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-04-30 | Wells Fargo | → Overweight |
| 2026-04-30 | JP Morgan | → Neutral |
| 2026-04-30 | Goldman Sachs | → Neutral |
| 2026-04-30 | Evercore ISI Group | → Outperform |
| 2026-04-30 | Citigroup | → Neutral |
| 2026-04-30 | Barclays | → Equal-Weight |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-29 | Reg FD Disclosure, Exhibits | read |
| 2026-07-29 | Earnings Release, Exhibits | read |
| 2026-07-23 | Earnings Release, Officer / Director Change… | read |
| 2026-05-11 | Shareholder Vote, Other Material Event | read |
| 2026-04-29 | Earnings Release, Exhibits | read |
| 2026-03-17 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-02-27 | Material Agreement, Termination of Agreement… | read |
| 2026-02-04 | Earnings Release, Exhibits | read |
| 2025-12-15 | Material Agreement, Material Obligation… | read |
| 2025-12-02 | Other Material Event, Exhibits | read |
| 2025-10-29 | Earnings Release, Exhibits | read |
| 2025-07-30 | Earnings Release, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-22 | Lobo Kevin | Buy | 10.00K | $641.80K | |
| 2026-05-15 | Bankes Jeannette | CEO, Patient Care Solutio | Withheld for tax | 5.54K | $346.88K |
| 2026-05-15 | Rackliffe Philip | CEO, AIS | Grant | 16.46K | — |
| 2026-05-12 | Hochman Rodney F | Buy | 1.62K | $100.36K | |
| 2026-05-08 | Yang Watkin Phoebe L. | Buy | 1.00K | $63.01K | |
| 2026-05-07 | Hochman Rodney F | Grant | 2.69K | — | |
| 2026-05-07 | LESJAK CATHERINE A | Grant | 3.59K | — | |
| 2026-05-07 | Lobo Kevin | Grant | 3.59K | — | |
| 2026-05-07 | Madden Anne T | Grant | 3.59K | — | |
| 2026-05-07 | Madden Anne T | Grant | 2.28K | — |
Flow & Concentration
| Insider 180d net | $805.17K |
|---|---|
| Insider buys / sells | 3 / 0 |
| Insider bias | Neutral |
| 13F holders | 0 |
| Top-5 share | 0.0% |
| HHI | 0 (—) |
Dividends
| Yield (TTM) | 0.16% |
|---|---|
| $ / share (TTM) | $0.11 |
| 5y CAGR | — |
Annual dividend per share
| 2023 | $0.09 |
|---|---|
| 2024 | $0.12 |
| 2025 | $0.14 |
| 2026 | $0.07 |
SEC Filings
The Long Run
FY 2023–2025 · 3 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $19.55B | +3.2% | |
| Gross profit | $8.21B | +6.9% | |
| Operating income | $2.44B | -6.7% | |
| Net income | $2.08B | -3.7% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $66.20 | $67.01 | $65.75 | $66.63 | 4.16M |
| Sep 24 | $66.14 | $66.48 | $65.19 | $66.38 | 3.97M |
| Sep 23 | $66.16 | $66.46 | $65.62 | $66.09 | 3.17M |
| Sep 22 | $66.28 | $67.09 | $66.00 | $66.27 | 3.94M |
| Sep 21 | $64.24 | $65.10 | $63.71 | $64.81 | 3.50M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →